It might be easy to dismiss non-life-threatening diseases of the skin or nail as trivial, but their impact on physical and mental wellbeing can be significant. Such diseases are obvious targets for topical treatments, but the lack of effective formulations means patients are often faced with the prospect of oral…
List view / Grid view
The company announced the voluntary recall is due to low, out of specification dissolution test results in specific batches of its tetracycline products.
The US FDA will fund a research project using Raman spectroscopy and mass spectrometry to study drug delivery via the skin.
After a review of cyproterone, the EMA has recommended that the drug only be prescribed once other treatment options have failed, due to an increased meningioma risk.
As companies continue to collaborate and share their expertise to develop therapeutics targeting a wide range of diseases, European Pharmaceutical Review explores the aims of the most recent partnerships.
Seven medications have been suggested for removal from prescriptions by the NHS after a public consultation.